Intelligence / Healthtech / De Novo Grants / Myocene
Approvalsnovel device granted (FDA De Novo)17 Jan 2025
Myocene
17 Jan 2025: Novel device granted (FDA De Novo) · Myocene. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 17 Jan 2025
- Device
- Myocene
- Specialty
- Neurology
- Product Code
- SDX
- Country
- Belgium
- Location
- Liège, Belgium
- Submitted
- 2023-07-27
- Reference
- DEN230051
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Myocene
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Neurology
De Novo Grants
21 AugMatap Ii, LLCnovel device granted (FDA De Novo) · AvuluxApprovals8 MayNeurovalens Limitednovel device granted (FDA De Novo) · Modius SperoApprovals3 AprAutomated Imaging Diagnostics, LLCnovel device granted (FDA De Novo) · neuropacsApprovals14 NovFusmobile, Inc.novel device granted (FDA De Novo) · Neurolyser XR (NXR100)Approvals6 OctPainchek Limited (Ltd.)novel device granted (FDA De Novo) · PainChek (PainChek Adult)Approvals20 AugQuantalx Neuroscience, Ltd.novel device granted (FDA De Novo) · Delphi-MD SystemApprovals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.